The effects of kefir consumption on human health: a systematic review of randomized controlled trials.

cultured milk products dairy products gut microbiome kefir microbiome oral microbiome probiotics

Journal

Nutrition reviews
ISSN: 1753-4887
Titre abrégé: Nutr Rev
Pays: United States
ID NLM: 0376405

Informations de publication

Date de publication:
10 02 2023
Historique:
pubmed: 2 8 2022
medline: 14 2 2023
entrez: 1 8 2022
Statut: ppublish

Résumé

Kefir, a traditional, fermented-milk beverage, has increasingly been promoted for various health benefits. The evidence from systematic reviews, however, is limited. Evidence from randomized controlled trials testing oral consumption of fermented-milk kefir on any outcome of human health or disease. A systematic search of 4 electronic databases (PubMed, Scopus, Allied and Complementary Medicine Database, and Cochrane Trials) from inception to July 31, 2021, was conducted. Data extraction and risk-of-bias assessments were conducted by 2 reviewers independently. A total of 18 publications reporting the results of 16 studies were included. Per the narrative analysis, fermented-milk kefir may have potential as a complementary therapy in reducing oral Streptococcus mutans, thereby reducing dental caries risk, and in Helicobacter pylori eradication therapy. Kefir may further aid treatment of adult dyslipidemia and hypertension, although evidence was very limited. Safety was only assessed in 5 of the 18 included publications, and 12 of the studies had an overall high risk for bias. Kefir is a dairy product with a unique microbiological profile that appears to be a safe for generally healthy populations to consume. However, efficacy and safety data from high-quality human trials are essential before any recommendations may be made for conditions of the oral and gastric microbiota and metabolic health. PROSPERO registration no. CRD42020211494.

Identifiants

pubmed: 35913411
pii: 6652871
doi: 10.1093/nutrit/nuac054
doi:

Types de publication

Journal Article Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

267-286

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Lana Kairey (L)

are with the National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia.

Bradley Leech (B)

are with the National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia.

Fatima El-Assaad (F)

is with the University of New South Wales (UNSW) Microbiome Research Centre, St George and Sutherland Clinical School, UNSW Sydney, Sydney, New South Wales, Australia.

Andrea Bugarcic (A)

are with the National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia.

Drew Dawson (D)

is with the Central Queensland University, Wayville, South Australia, Australia.

Romy Lauche (R)

are with the National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH